Abbott Completes Acquisition of IDEV Technologies
ABBOTT PARK, Ill., /PRNewswire/ -- Abbott (NYSE: ABT) today announced that it has completed its acquisition of IDEV Technologies, a privately held company focused on developing next-generation medical devices for use by interventional radiologists, vascular surgeons and interventional cardiologists.
The acquisition expands Abbott's global peripheral technology portfolio with IDEV Technologies' SUPERA Veritas self-expanding nitinol stent system. SUPERA Veritas has CE Mark in for treating blockages in blood vessels due to peripheral artery disease (PAD). In the U.S., SUPERA Veritas is cleared only for the treatment of biliary strictures (narrowing of a bile duct) related to cancer. It is currently being reviewed under a Premarket Approval application by the U.S. Food and Drug Administration for treatment of the superficial femoral artery, which is the main artery in the thigh that supplies blood to lower extremities, and is not currently approved in the U.S. for that use.
With its proprietary interwoven wire technology, SUPERA Veritas is designed based on biomimetic principles attempting to mimic the body's natural movement to promote blood flow in the treated area while offering strength and flexibility. A recent publication in the cited that more than 200 million people worldwide are living with PAD.
"Peripheral artery disease is a significant and growing health concern around the world, raising the need for new and effective treatment options," said , senior vice president, vascular, Abbott. "Abbott's acquisition of IDEV Technologies strengthens our global product portfolio while providing an additional opportunity to make a positive impact in the lives of patients with peripheral artery disease."
Abbott acquired all outstanding equity of IDEV Technologies for net of cash and debt.
In patients with PAD, fatty deposits accumulate on the inner wall of the artery, causing blockages that reduce the flow of blood to lower parts of the leg. Patients with PAD can experience leg pain when walking and, if untreated, the disease can progress with severe consequences such as critical limb ischemia and amputation.
Abbott Vascular is the world's leader in drug eluting stents. Abbott Vascular has an industry-leading pipeline and a comprehensive portfolio of market-leading products for cardiac and vascular care, including products for coronary artery disease, vessel closure, endovascular disease and structural heart disease.
Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 70,000 people.
Visit Abbott at www.abbott.com and connect with us on Twitter at @AbbottNews.
Fowkes FGR, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. 2013; http://dx.doi.org/10.1016/ S0140-6736(13)61249-0.